Presentation of Carfilzomib Associated Thrombotic Microangiopathy

Journal of Infectious Diseases Case R eport Presentation of Carfilzomib Associated Throm- botic Microangiopathy William Stolar ek, Catherine Abern* 1. University in Madison, Wisconsin, US 2. Department of Sur gery, Emory university school of medicine, Atlanta, US Corresponding Author Catherine Abern* Department of Sur gery, Emory university school of medicine, Atlanta, US, Email: [email protected] Received Date: Nov 20, 2021 Accepted Date: Nov 22, 2021 Published Date: Dec 19, 2021 Abstract Multiple Myeloma (MM) may be a lymph cell disorder characterised by abnormal proliferation of plasma cells leading to overrun of para- protein. Proteasome inhibitors (PI) are a corner stone for the treatment of millimetre. TMA results in end-organ harm and infarct by micro- thromobi. TMA pathophysiology isn’t well understood and has multiple etiologies. we tend to gift a case of PI-induced TMA, in conjunction with literature review of cases diagnosed from 2008-2018. distinctive to our case is that the onset of presentation, over twenty four months when initiating carfilzomib. Our case highlights the necessity for open-eyed observance and also the importance of clinical suspicion in patients in danger for TMA. Keywords carfilzomib, thrombotic microangiopathy , proteosome inhibitos Introduction Multiple Myeloma (MM) may be a lymph cell disorder characterised by abnormal proliferation of plasma cells leading to overrun of parapro- tein. It represents concerning 100% of hematologic malignancies with associate incidence of twenty seven,000 each year [1]. Treatment typi- cally includes therapy and in patients with superb response to therapy, more treatment with autologous organic process vegetative cell trans- plant (HSCT) [2]. Proteasome inhibitors (PI) are a corner stone for the treatment of mil- limetre [3,4,5] beginning with bortezomib a reversible PI that was ap- proved in 2003, then the introduction of carfilzomib, associate irrevers- ible and selective PI, that was approved in 2012. Carfilzomib was ab initio approved for treatment of refractory millimetre, however because of higher rates of response and improved survival, it has been progres- sively used each as a first-line medical aid and at relapse [6]. Well known aspect effects of PI embrace peripheral pathology, general and pulmonic high blood pressure, coronary failure, anemia, fatigue, thrombopenia, nausea, pyrexia, dyspnea, diarrhea, headache, and cough [7]. Most grade three and four adverse effects (medically vital adverse events leading to hospitalization, morbidity or life threatening) area unit hematologic and embrace thrombopenia (23.4%), anemia (22.4%), and lymphopenia (18.1%) [8].

However, a probably fatal, underreported, and comparatively recently discovered adverse result is thrombotic microangiopathy (TMA) that involves epithelium cell injury and activation of the clotting cascade, inflicting thrombopenia and microangiopathic anaemia (MAHA). This cascade of events results in ultimate widespread microvascular occlu- sion and end-organ infarct. apparently whereas bortezomib has been gift for nearly a decade before carfilzomib, and has broader indications to be used, most of the reportable bortezomib-induced TMA cases were collected when carfilzomib use, seemingly because of height- ened awareness of this serious complication. Hobeika et al. reportable the primary case of carfilzomib-induced urinary organ thrombotic mi- croangiopathy on a urinary organ diagnostic assay in 2014 [9]. The reportable cases of this development occurred terribly shortly when initiation of treatment. Here, we tend to report a case of delayed onset carfilzomib-induced TMA occurring when receiving continuous medi- cal aid for 2 years. Case Pr esentation A 65-year-old-female with IgG-kappa-MM, Revised myeloma Interna- tional Staging System (R-ISS) stage a pair of, diagnosed eight years past. She was ab initio treated with bortezomib associated adrenal cortical steroid (Vd) with superb response then an autologous organic process vegetative cell transplant. Post-transplant, she was treated with lenalidomide maintenance for thirteen months however eventually had illness progression. Second line treatment with bortezomib, cyclophos- phamide and adrenal cortical steroid (VCD) was initiated, completed seven months of treatment. Her illness eventually progressed, and he or she was switched to carfilzomib, adrenal cortical steroid and poma- lidomide (KPd). The patient achieved complete remission when eight cycles of KPd then continuing maintenance medical aid with carfilzo- mib monotherapy for one uear till relapse. She was people with (KPd), achieving superb partial response when four cycles. At patient request, her treatment was de-escalated to carfilzomib and adrenal cortical ste- roid (Kd) solely. The millimetre remained in restraint, the patient re- ceived a pair of cycles of Kd then bestowed with complaints of fatigue, lethargy, cough and symptom. Laboratory tests were exceptional for acute kidney disease, thrombopenia, and solution abnormalities. Cre- atinine was severely elevated at eleven mg/dL (baseline of zero.67 mg/ dL), acid fifteen mg/dL, calcium 6.7 mg/dL, and phosphorus five.6 mg/ dL. hemoprotein was at her baseline of eleven.5 gm/dL, RBC one.78%, traditional haematoidin, and peripheral blood smear was ordinary while not schistocytes. clotting parameter coagulation factor and activated clotting factor time were traditional. She was suspected to possess neoplasm Lysis Syndrome (TLS) and al- lotted a Cairo-Bishop grade four, as creatinine rose over vi times the baseline, indicating severe TLS. The patient was hydrous smartly and given a dose of rasburicase.It represents organic chemistry markers of TLS at baseline and for the primary four days of her hospital keep. The development of anemia and thrombopenia with laboratory proof of microangiopathic hematolysis raised the suspicion for carfilzomib www.directivepublications.org/ Page - 01

Journal of Infectious Diseases Case R eport induced-TMA. ADAMTS13 activity level was forty eighth that domi- nated out thrombotic

thrombocytopenic purpura (TTP). alternative causes of TMA like dis- seminated intravascular clotting, mechanical valve, and uncontrolled high blood pressure were dominated out. It shows the initial and fol- low-up hematolysis parameters. Hemodialysis and ancillary care were continuing although the patient’s hospital course was sophisticated by bodily cavity and gi harm that was managed with a nucleon pump substance continuous drip. One week when hospitalization, the platelets and hemoprotein improved to close baseline and also the patient was eventually discharged. She sadly re- mained addicted to haemodialysis. Discussion TMA encompasses a spectrum of 3 totally different conditions: hae- molytic azotemic syndrome, atypical haemolytic azotemic syndrome (aHUS) and TTP; sharing the triad of Dhegiha, thrombopenia and kid- ney failure, however with totally different deed and presentation. best- known etiologies for TMA may be hereditary and acquired; hereditary etiologies embody ADAMTS13 deficiency and mutations touching the choice complement pathway. nonheritable causes of TMA embody in- fections, drug iatrogenic, and MM, that has been concerned as a reason for TMA significantly in cases of uncontrolled metric linear unit at the time of initial diagnosing. HSCT has additionally been related to Dhegiha and TMA, classified below a class known as transplant-associ- ated thrombotic microangiopathy (T A-TMA) [10,1 1,12,13]. Drug iatrogenic TMA (DITMA) has been reportable with the utilization of various medications like quinines, clopidogrel, calcineurin inhibi- tors, cyclosporin, vascular epithelial tissue protein (VEGF) inhibitors, and chemotherapeutical agents like gemcitabine, antibiotic drug and proteasome inhibitors just like the subject in our case, PI [14,15,16]. There square measure many postulated mechanisms of PI iatrogenic TMA. One hypothesis is predicated on immune-mediated toxicity, as PIs could lead on to high levels of unhealthy cytokines (including IL-6 and TNF-a), and build a microvascular surroundings giving the forma- tion of drug-dependent antibodies [17]. Another mechanism is dose-mediated toxicity involving VEGF inhi- bition resulting in microvascular injury, significantly to capillary ves- sel capillaries. the same as the mechanism by that bevacizumab (an- ti-VEGF antibodies), pazopanib (VEGF 1-3 inhibitor) and sunitinib (VEGF amino acid enzyme inhibitor) will result in TMA-related uri- nary organ harm specifically via podocyte injury, inflicting albuminuria and high blood pressure [14,18,19]. Our literature review exploitation PubMed with the keywords: carfil- zomib, bortezomib, proteasome inhibitors, TMA, thrombotic, microan- giopathy, HUS, AHUS and TTP unconcealed reports nineteen cases of DITMA attributed to PI use between 2008-2018. In 2016, Yui et al [20] reviewed an extra eleven cases at six major establishments in United States of America and Europe that weren’t enclosed as a result of the individual presentation and outcome for every case wasn’t such that. Ixazomib, the foremost recent PI has additionally been coupled to DIT- MA, and three reportable cases square measure enclosed.

Similar to our patient, larger than ninetieth of the patients reviewed had acute urinary organ injury and over half the cases reportable complaints of fatigue and lethargy probably thanks to the second commonest pre- senting symptoms of looseness of the bowels and unconditioned reflex. Onset of DITMA when PI exposure varied wide within the represented cases starting from hours up to seventeen months, with a median of for- ty six days. Our case is somewhat distinctive thanks to the terribly late onset of presentation of TMA when receiving carfilzomib for twenty three months. To the most effective of our information, presentation this so much out from initiation of treatment has not been reportable. Most of the reportable cases of PI iatrogenic TMA were managed with plasma exchange, transfusion, and chemical analysis. Twelve of nine- teen cases achieved full recovery with numerous therapeutic measures; hemodialysis, plasmapheresis, discontinuing the PI, and accessory transfusion. 2 patients achieved full recovery with combined measures: one received apheresis, dialysis and eculizumab, and therefore the alternative achieved full recovery with apheresis and rituximab. With the unpredictable responses to varied therapeutic in- terventions, we tend to square measure unable to draw any conclusions relating to treatment effectiveness and more understanding of the patho- physiology of DITMA ought to be investigated. Resolution of the DITMA when dialysis would possibly support the dose-dependent toxicity of the PI driving the DITMA, whereas its res- olution when apheresis, eculizumab associated rituximab support the idea of an immune mediate mechanism driving DITMA. Eculizumab may be a antibody against complement macromolecule C5 that inhibits the formation of C5a, a unhealthy protein. Complement targeted medical aid with eculizumab may be a well-established treat- ment for aHUS. 2 prospective studies revealed in 2013 all over that eculizumab is related to vital time-dependent improvement in nephrit- ic perform in patients with atypical Hus [34]. Cytopenias inside 3-5 weeks. However, its use remains off-label and there remains no normal of take care of PI-induced TMA. The mechanism of eculizumab would possibly offer United States of America with higher understanding of the immunologic response in drug-induced TMA, however this remains a locality for more study. Carfilzomib is apace changing into a corner-stone treatment in metric linear unit. Though TMA wasn’t reportable with the initial trials [35], it’s currently a recognized adverse result of carfilzomib. reportage ad- verse effects just in case series helps expand our information of the risks and edges of treatments. fast recognition of those symptoms and labo- ratory leads to relation to their temporal relationship to the initiation of PI also can save patients from potential fatal aspect effects, that can be reversible. Finally, our case highlights the necessity for alert observance and therefore the importance of clinical acumen and history taking in patients in danger for TMA, even when extended exposures to best- known contributive medicine. References 1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2015. CA Cancer J Clin, 2015. 65(1): p. 5-29. 2. Ludwig, H., et al., International Myeloma Working Group recommendations for global myeloma care. Leukemia, 2014. 28(5): p. 981-92. 3. Palumbo, A. and K. Anderson, Multiple myeloma. N Engl J Med, 201 1. 364(11): p. 1046-60. 4. Adams, J. and M. Kauffman, Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest, 2004. 22(2): p. 304-11. 5. Siegel, D.S., et al., A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory mul- tiple myeloma. Blood, 2012. 120(14): p. 2817-25. 6. Dimopoulos, M.A., et al., Carfilzomib and dexamethasone ver- sus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, www.directivepublications.org/ Page - 02

Journal of Infectious Diseases Case R eport phase 3, open-label, multicentre study. Lancet Oncol, 2016. 17(1): p. 27-38. 7. Chari, A. and D. Hajje, Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring. BMC Cancer, 2014. 14: p. 915. 8. Harvey, R.D., Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma re- ceiving single-agent carfilzomib. Clin Pharmacol, 2014. 6: p. 87-96. 9. Hobeika, L., S.E. Self, and J.C. Velez, Renal thrombotic mi- croangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. BMC Nephrol, 2014. 15: p. 156. 10. Noris, M. and G. Remuzzi, Atypical hemolytic-uremic syn- drome. N Engl J Med, 2009. 361(17): p. 1676-87. 11. Noris, M., et al., Relative role of genetic complement abnor- malities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol, 2010. 5(10): p. 1844-59. 12. Roy, V., et al., Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant, 2001. 27(6): p. 641-6. 13. Besbas, N., et al., A classification of hemolytic uremic syn- drome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int, 2006. 70(3): p. 423-31. 14. Eremina, V., et al., VEGF inhibition and renal thrombotic mi- croangiopathy. N Engl J Med, 2008. 358(1 1): p. 1 129-36. 15. Reese, J.A., et al., Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the BloodCenter of Wisconsin. Am J Hematol, 2015. 90(5): p. 406-10. 16. Al-Nouri, Z.L., et al., Drug-induced thrombotic microangiop- athy: a systematic review of published reports. Blood, 2015. 125(4): p. 616-8. 17. Moore, H. and K. Romeril, Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib. Intern Med J, 2011. 41(4): p. 348-50. 18. Eremina, V. and S.E. Quaggin, Biology of anti-angiogenic therapy-induced thrombotic microangiopathy. Semin Nephrol, 2010. 30(6): p. 582-90. 19. Usui, J., et al., Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth fac- tor inhibitors: a report of 5 cases and review of literature. Hum Pathol, 2014. 45(9): p. 1918-27. 20. Yui, J.C., et al., Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol, 2016. 91(9): p. E348-52. 21. Chan, K.L., et al., Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma. Leuk Lym- phoma, 2015. 56(7): p. 2185-6. 22. Mehta, N., A. Saxena, and R. Niesvizky, Bortezomib-induced thrombotic thrombocytopaenic purpura. BMJ Case Rep, 2012. 2012. 23. Salmenniemi, U. and K. Remes, Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. Hematol Rep, 2012. 4(2): p. e13. 24. Morita, R., et al., Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma. Int J Hematol, 2008. 88(2): p. 248-250. 25. Lodhi, A., et al., Thrombotic microangiopathy associated with proteasome inhibitors. Clin Kidney J, 2015. 8(5): p. 632-6. 26. Sullivan, M.R., et al., Carfilzomib associated thrombotic mi- croangiopathy initially treated with therapeutic plasma ex- change. J Clin Apher, 2015. 30(5): p. 308-10. 27. Qaqish, I., et al., Carfilzomib: A cause of drug associated thrombotic microangiopathy. Transfus Apher Sci, 2016. 54(3): p. 401-4. 28. Gosain, R., et al., Gemcitabine and carfilzomib induced throm- botic microangiopathy: eculizumab as a life-saving treatment. Clin Case Rep, 2017. 5(12): p. 1926-1930. 29. Chen, Y., et al., Thrombotic microangiopathy during carfilzo- mib use: case series in Singapore. Blood Cancer Journal, 2016. 6: p. e450. 30. Atrash, S., et al., Fatal Thrombotic Microangiopathy Develop- ing within 24 Hours of Carfilzomib in a Patient with Relapsed Multiple Myeloma (MM). Blood, 2012. 120(21): p. 5037- 5037. 31. Van Keer, J., et al., Renal Thrombotic Microangiopathy Asso- ciated with the Use of Bortezomib in a Patient with Multiple Myeloma. Case Rep Hematol, 2016. 2016: p. 6020691. 32. Yui, J.C., A. Dispenzieri, and N. Leung, Ixazomib-induced thrombotic microangiopathy. Am J Hematol, 2017. 92(4): p. E53- e55. 33. Atallah-Yunes, S.A. and M.H. Soe, Drug-Induced Thrombot- ic Microangiopathy due to Cumulative Toxicity of Ixazomib. Case Rep Hematol, 2018. 2018: p. 7063145. 34. Legendre, C.M., et al., Terminal complement inhibitor eculi- zumab in atypical hemolytic-uremic syndrome. N Engl J Med, 2013. 368(23): p. 2169-81. 35. Stewart, A.K., et al., Carfilzomib, lenalidomide, and dexa- methasone for relapsed multiple myeloma. N Engl J Med, 2015. 372(2): p. 142-52. www.directivepublications.org/ Page - 03

This is an automatically generated text version. For the formatted version of record, download the PDF →